A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

Mise à jour : Il y a 4 ans
Référence : NCT01682902

Femme et Homme

Extrait

This trial is conducted in the United States of America (USA). The aim of the trial is to evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog® in subjects with type 1 diabetes.


Critère d'inclusion

  • diabetes ,Diabetes Mellitus, Type 1

Liens